Zongertinib’s NEJM Debut Signals New Hope for HER2-Mutant Lung Cancer

RIDGEFIELD, CT – April 16, 2026 – A new era in the treatment of a rare and aggressive form of lung cancer has been validated by one of the world's most prestigious medical journals. Data published today in The New England Journal of Medicine (NEJM) showcases the powerful and durable efficacy of zongertinib (brand name HERNEXEOS®), an oral targeted therapy developed by Boehringer Ingelheim for patients with HER2-mutant non-small cell lung cancer (NSCLC).

The publication details results from the Phase 1b Beamion LUNG-1 trial, which evaluated zongertinib as a first-line treatment for patients who had not previously received therapy for their advanced disease. The findings represent a significant breakthrough for a patient population that has historically faced a grim prognosis with limited effective options.

A New Standard of Care Emerges

The trial results, first presented in part at major oncology conferences, now receive their full scientific validation in the NEJM manuscript, titled "First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer." The data from 74 treatment-naïve patients is striking: an impressive 76% saw their tumors shrink, a measure known as the confirmed objective response rate (ORR). Within that group, 11% of patients achieved a complete response, meaning scans showed no remaining evidence of their cancer.

Crucially, these responses were not fleeting. The median duration of response (mDoR) was 15.2 months, and patients lived for a median of 14.4 months without their cancer progressing (median progression-free survival, or mPFS). These figures stand in stark contrast to the outcomes typically seen with traditional platinum-based chemotherapy, which has long been the standard of care but offers far more modest benefits in this specific patient group.

"This data shows zongertinib demonstrated durable efficacy as first-line therapy in treatment-naïve patients with HER2-mutant advanced non-small cell lung cancer, a setting where there are currently limited options with durable responses," said Dr. John Heymach, the coordinating investigator for the trial and chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. "These findings, now published in The New England Journal of Medicine, may help healthcare providers make informed decisions on HER2 targeted treatment choices."

Perhaps one of the most critical findings addresses a common and devastating complication of this disease: the spread of cancer to the brain. The study included 30 patients with active brain metastases, and nearly half of them (47%) experienced a confirmed intracranial objective response. This demonstrates zongertinib’s ability to cross the blood-brain barrier and attack tumors in the central nervous system, a key attribute for any effective therapy in this setting.

Targeting an Aggressive and Underserved Cancer

Lung cancer remains the world's deadliest cancer, and while NSCLC is the most common type, it is not a single disease. It is a collection of distinct cancers defined by specific genetic drivers. Mutations in the HER2 gene (also known as ERBB2) are responsible for driving the cancer in a small but significant subset of patients—approximately 1% to 4% of all NSCLC cases. These mutations, which are more common in women and non-smokers, lead to the overactivation of the HER2 protein, fueling uncontrolled cell growth and tumor spread.

Historically, patients diagnosed with HER2-mutant advanced lung cancer faced a poor prognosis, with median survival often measured in months, not years. Zongertinib is a highly selective, irreversible tyrosine kinase inhibitor (TKI) designed specifically to shut down the aberrant HER2 signaling pathway. Its precision allows it to target the cancer-driving mutation while largely sparing the related EGFR protein, a mechanism that helps mitigate some of the severe side effects, like rash and diarrhea, that have plagued earlier generations of less-selective TKIs. The Beamion LUNG-1 trial reported that treatment-related adverse events were predominantly low-grade, with only 9% of patients needing to discontinue the therapy due to side effects.

Navigating the Fast Track to Patients

The strong clinical data has already paved an accelerated path for HERNEXEOS to reach patients in need. Recognizing the drug’s potential to address a critical unmet need, the U.S. Food and Drug Administration (FDA) recently granted it accelerated approval for the first-line treatment of adult patients with unresectable or metastatic NSCLC harboring specific HER2 mutations. This followed a prior accelerated approval for its use in patients who had already received other treatments.

This rapid regulatory pathway was supported by the FDA's Breakthrough Therapy Designation, which is reserved for drugs that demonstrate substantial improvement over available therapies for serious conditions. The accelerated approval is based on the response rate and duration of response seen in the trial. As is standard for this pathway, continued approval is contingent upon the results of a larger, confirmatory trial.

That confirmatory study, a Phase III trial named Beamion LUNG-2, is currently enrolling patients. It will formally evaluate zongertinib against the standard of care in the first-line setting and is essential for converting the accelerated approval into a full, permanent one. Boehringer Ingelheim is also investigating the drug in earlier stages of the disease with the Beamion LUNG-3 trial, which will assess its potential as a therapy after surgery to prevent cancer recurrence.

Reshaping the Treatment Landscape

Zongertinib's emergence as a first-line therapy fundamentally reshapes the treatment strategy for HER2-mutant NSCLC. Until now, the only other HER2-targeted therapy approved for this cancer was an antibody-drug conjugate, trastuzumab deruxtecan, which is indicated for patients whose cancer has progressed after a prior line of therapy. While effective, it is an intravenous treatment with its own set of significant toxicities.

With HERNEXEOS, clinicians now have a potent, targeted, once-daily oral pill they can offer patients from the moment of their advanced diagnosis. The convenience of an oral medication, combined with a manageable safety profile and robust efficacy, represents a major step forward in improving not only survival but also the quality of life for those living with this disease. The publication of this data in the NEJM solidifies the scientific foundation for this new approach and establishes zongertinib as a pivotal agent in the personalized treatment of lung cancer. With the confirmatory Beamion LUNG-2 trial now underway, the oncology community is watching closely as this promising therapy works to secure its role as a definitive standard of care for this challenging disease.